Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07376265 · ClinicalTrials.gov registry record
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,249
- Enrollment target
NCT07376265: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07376265 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,249 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07376265 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,249 participants
- Enrollment target
Study Summary
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectiveness of sacubitril/valsartan (SAC/VAL) versus angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with heart failure with reduced ejection fraction (HFrEF).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,249 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2024-04-11 |
What the finished NCT07376265 record still lists
NCT07376265 is an observational study that tracks outcomes without assigning an intervention. Its 1,249 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07376265 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07376265 about?
NCT07376265 is a clinical study titled "A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients". This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectivene...
What is the current status of trial NCT07376265?
This trial is currently completed. The enrollment target is 1,249 participants. The study started on 2023-10-20. Estimated completion is 2024-04-11.
Who is sponsoring clinical trial NCT07376265?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI